Evidence for the presence of lipopolysaccharide in a ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa
Evidence for the presence of lipopolysaccharide in a ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa
复制标题
铜绿假单胞菌核糖核酸酶敏感核糖体疫苗中存在脂多糖的证据
DOI：
--
复制
发表时间：
1981
影响因子：
3.1
通讯作者：
C. V. van Boven
中科院分区：
文献类型：
--
作者：
R. Gonggrijp;M. P. Volleberg;P. Lemmens;C. V. van Boven
为了获得有关铜绿假单胞菌核糖体疫苗（组分II）中免疫原性质的信息，我们研究了兔抗体对组分II的特异性。交叉免疫电泳表明存在的抗体沉淀与核糖体抗原，但不与脂多糖（LPS）。通过酶联免疫吸附试验，在组分II的抗体中检测到LPS抗体。组分II的抗体可以保护小鼠免受铜绿假单胞菌的致命攻击。吸收实验表明，部分II的抗体的保护能力是由于抗体的细胞包膜抗原，而核糖体抗原的抗体没有贡献的保护。LPS的抗体可以检测到小鼠1周后，单次接种组份II。可以得出结论，组分II的保护活性至少部分是由于核糖体疫苗中LPS的存在。用核糖核酸酶处理组分II降低了核糖体疫苗的保护活性。添加合成的聚腺苷酸-聚尿苷酸恢复了核糖核酸酶处理的组分II的保护活性，表明核糖体疫苗中的RNA可能在污染细胞包膜抗原的呈递中充当佐剂或载体。将级分II的保护活性和毒性与级分I的保护活性和毒性进行比较，所述级分I含有细胞包膜组分，包括LPS和纯化的LPS。结果表明，核糖体疫苗的保护作用与比组分I的保护作用稍高的毒性有关，而纯化的LPS是毒性最大的疫苗。
To obtain information about the nature of the immunogens in the ribosomal vaccine (fraction II) of Pseudomonas aeruginosa, we studied the specificity of rabbit antibodies to fraction II. Crossed immunoelectrophoresis demonstrated the presence of antibodies which precipitated with ribosomal antigens, but not with lipopolysaccharide (LPS). By means of an enzyme-linked immunosorbent assay, antibodies to LPS were detected in antibodies to fraction II. Antibodies to fraction II could protect mice against a lethal challenge with P. aeruginosa. Absorption experiments demonstrated that the protective ability of antibodies to fraction II was due to antibodies to cell envelope antigens, whereas antibodies to ribosomal antigens did not contribute to the protection. Antibodies to LPS could be detected in mice 1 week after a single vaccination with fraction II. It was concluded that the protective activity of fraction II was due, at least in part, to the presence of LPS in the ribosomal vaccine. Treatment of fraction II with ribonuclease decreased the protective activity of the ribosomal vaccine. Addition of synthetic polyadenylic acid-polyuridylic acid restored the protective activity of ribonuclease-treated fraction II, indicating that RNA in the ribosomal vaccine might act as an adjuvant or a carrier in the presentation of the of the contaminating cell envelope antigens. The protective activity and the toxicity of fraction II were compared with the protective activity and the toxicity of fraction I, which contained cell envelope components, including LPS, and of purified LPS. The results indicated that protection by the ribosomal vaccine was associated with a slightly higher toxicity than was protection by fraction I, whereas purified LPS was the most toxic vaccine.